Aurinia Pharmaceuticals Inc (AUPH) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

AUPH scores 77 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

• Fundamental Cash Engine: 13 / 20 (ROIC 16.5%; FCF yield 5.92%). This is the cash-generation view. The ROIC and FCF yield figures indicate the business is currently producing returns, though the pillar score sits in the middle of its range.
• Whale 13F Flow: 14 / 20 (institutional accumulation and options positioning). The score reflects moderate institutional support. The source does not provide the underlying 13F holdings detail, so the magnitude of accumulation cannot be verified here.
• Insider Conviction: 17 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the strongest of the market-signal pillars, suggesting insider and disclosed-trade activity is net supportive, though the individual trades are not itemized in the source.
• Macro Regime Fit: 15 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is modeled to move in line with the broad market, so it neither amplifies nor dampens market swings.
• Forensic Balance Sheet: 18 / 20 (Altman Z 8.33; Piotroski F 7/9; Debt/Equity 0.5). This is the highest-scoring pillar. An Altman Z of 8.33 and Piotroski F of 7 out of 9 point to strong financial health, and Debt/Equity of 0.5 indicates moderate leverage.

For a prospective investor, the upside drivers are the balance-sheet strength and the supportive insider and institutional signals. The valuation tradeoff is that the stock trades at a trailing P/E of 8 and a forward P/E of 6.7, which can reflect either undervaluation or market skepticism about durability; the source does not resolve which. The 13/20 cash-engine score signals that cash generation, while present, has not yet reached the strength of the balance-sheet pillar. These are analytical observations, not personalized advice.

Aurinia Pharmaceuticals Inc (AUPH) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..3B. —

Revenue rose from $175.5M in FY 2023 to $283.1M in FY 2025, and operating income moved from a loss of -$91.7M to $104.9M over the same span. Per the market data, gross margin is 88.5%, operating margin 37.1%, and net margin 68%, with ROIC at 16.5%. The Altman Z-Score of 8.33 and Piotroski F-Score of 7/9 are cited in the RQD pillar detail. Debt/Equity is 0.5 per that same detail; the debt line in the SEC financials is not reported.

• 🐂 Primary Bull Case: Revenue grew from $175.5M to $283.1M over FY 2023–FY 2025 while operating income swung to $104.9M, supported by a strong balance-sheet pillar of 18/20. With Fundamental Cash Engine at 13/20 (ROIC 16.5%, FCF yield 5.92%) and Institutional Whale Flow at 11/20, sustained execution supports upside toward the top of the $12.79 – $19.25 52-week range.
• 🐻 Primary Bear Case: The source data cannot resolve conflicting Q3 earnings characterizations, and the business description, debt figure, and EPS are missing. Investors must weigh 8.0x trailing P/E and 21.1x EV/EBITDA against 37.1% operating margins and a 1.00 macro beta if sector demand softens.

— for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks.

• Key Question #1: What are the company's specific products, and what share of the FY 2025 revenue comes from each?
• Key Question #2: Which Q3 earnings characterization is accurate, given conflicting headlines?
• Key Question #3: What is the reported debt balance, and what drives the 0.5 Debt/Equity figure?